Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.
about
Immunostimulatory Gene Therapy Using Oncolytic Viruses as VehiclesSunitinib: the antiangiogenic effects and beyondAdjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate VaccinationPro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic TargetsSignal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapyA rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development.Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.Myeloid-derived Suppressor Cells are Necessary for Development of Pulmonary Hypertension.The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.Folate-Hapten-Mediated Immunotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer.Myeloid-derived suppressor cells as effectors of immune suppression in cancer.Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro.Therapeutic Cancer Vaccines.Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine.Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.Janus-Faced Myeloid-Derived Suppressor Cell Exosomes for the Good and the Bad in Cancer and Autoimmune Disease.Targeting tumour microenvironment by tyrosine kinase inhibitor.Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment.Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells.Targeting VEGF/VEGFR to Modulate Antitumor Immunity.Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration.Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis
P2860
Q26777403-1FC36D7B-1CB5-4DF9-A359-3442AF7798E3Q28066499-DC145262-47A0-4EB3-B63A-3C1D733DA2D1Q28074536-C0F648FF-F4A2-41D4-B50D-F280E3CD802DQ28076161-377D8C88-72B4-40DC-9339-A65451FE877AQ28080262-D24D1C90-B6D9-4162-BE1D-B38A57C6DF98Q36107975-217CC594-884F-44CD-B523-A7B7642A45B1Q37687194-BCFBC8D4-46FA-46E1-B095-BCD3EF4E7D13Q38597953-4D0CAD8A-497A-4AEB-AE26-20C7A9894256Q38666253-1205EBCC-9115-4EF4-9CE6-9A515364D08CQ38726025-8F4D2D85-B5E2-462F-96B9-4A14BCE2DB09Q38864758-02F3766D-F4CD-43A4-AFBD-B7E7E488F9D0Q38948897-C2E9FBCE-8138-4A26-B357-D0E0ECF9DB99Q39034031-FCC4D68D-B280-4AD9-8BD2-3418510EA6A6Q40032613-7EE2ADD4-9DD0-4F8B-8CCC-233CB688A3CCQ40728648-E05BC1E4-5764-44D3-9466-B363C34398A9Q42368949-B14B214A-87A7-4468-A0B9-E9C9678B168DQ47629566-DCB131C1-9059-457F-A0A9-E71372360AC1Q49884887-33933C04-AE42-4F52-BB29-62C7268A9816Q49887906-D90E6E50-8371-4086-95BC-7969A9D05FC5Q50546690-DCADED59-272F-42BA-8176-8D63D311BF68Q51097491-9C59EE21-7165-4644-95C9-33DDAD810A4DQ52682465-A6099757-E6FB-4355-B9D2-CF9FD3B01CC5Q52758913-92163A76-2112-422B-A847-089C0F4F0E6BQ55008337-A8F5D3BD-A37F-483E-9F11-2201379BDBF9Q55380684-C20ACC23-816A-40C0-8525-03A42B533FBDQ57299995-1BE8A2A2-5B99-4A8E-BDD4-CD0E9C7C29E7
P2860
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Sunitinib depletes myeloid-der ...... sponses and tumor eradication.
@ast
Sunitinib depletes myeloid-der ...... sponses and tumor eradication.
@en
type
label
Sunitinib depletes myeloid-der ...... sponses and tumor eradication.
@ast
Sunitinib depletes myeloid-der ...... sponses and tumor eradication.
@en
prefLabel
Sunitinib depletes myeloid-der ...... sponses and tumor eradication.
@ast
Sunitinib depletes myeloid-der ...... sponses and tumor eradication.
@en
P2093
P2860
P1433
P1476
Sunitinib depletes myeloid-der ...... sponses and tumor eradication.
@en
P2093
Baukje Nynke Hoogeboom
Hans W Nijman
Oana Draghiciu
P2860
P304
P356
10.4161/2162402X.2014.989764
P577
2015-01-07T00:00:00Z